Patient benefit and blood tests
Which tests measured a change you'd notice?
Scans measured patients' fat; blood tests measured hormone rises. Mice had strength and movement tests. You can see which tests concerned people and which benefits remain unproved.
Which result established a benefit in patients?
With tesamorelin, HIV patients lost fat surrounding internal belly organs [13][14][15][17]. HIV and treatment had affected where their fat gathered. Your own weight problem may have a different cause.
That patient benefit differs from a changed blood hormone number.
Healthy adults had raised blood hormones with CJC-1295 [3][4][5]. Growth hormone briefly increased in people given ipamorelin [9]. But its Phase 2 bowel study didn't prove earlier meals [8]. That phase means early testing of treatment benefit.
A hormone rise didn't establish quicker bowel recovery for you.
MOTS-c work involved cells, animals, and people's natural blood levels [18][19][20][21][22]. The human studies didn't give MOTS-c as a treatment. Their blood readings can't establish that a shot helps you.
You need the hoped-for improvement tested directly in people.
The natural hormone prompting your growth hormone gland is copied by tesamorelin and CJC-1295. Ipamorelin acts where your hunger hormone attaches. MOTS-c tests mainly concerned cells using fuel and muscle changes. Those differences don't establish equal health benefits.
Sugar entering mouse muscle doesn't prove stronger muscles in people. Mouse treadmill tests don't measure human recovery after surgery. Your own benefit needs the relevant change measured in people.
Who was tested, and what was actually measured?
| Peptide | What changed or was tested? | who was tested? | What does that leave unknown for you? | What did human tests establish? |
|---|---|---|---|---|
| CJC-1295 | Hormones stayed higher with the lasting form. The extra DAC part joins albumin in blood. | Healthy adults in small studies. | Whether higher blood levels improve health. | Hormone changes rather than proved health benefits [3][4][5]. |
| Ipamorelin | A brief hormone rise; the wait until meals after surgery. | Healthy men and bowel-surgery patients. | Long-term safety and wider recovery claims. | Its Phase 2 test didn't prove earlier meals [8][9]. |
| Tesamorelin | Reduced fat surrounding internal belly organs. | HIV patients with uneven fat buildup. | Whether a different fat disorder responds equally. | Fat reduction supporting approval for the tested disorder [13][14][15][17]. |
| MOTS-c | Mouse muscle and movement; natural human blood levels. | Mice, cells, and people whose kidneys needed dialysis. | Whether treatment helps or harms people. | natural blood levels associated with later health problems [18][19][20][21][22]. |
Those differing findings can't select your medical treatment. Tesamorelin's fat-loss benefit concerns one disorder. You don't have equally proved fat loss with CJC-1295.
Ipamorelin's Phase 2 study didn't establish quicker recovery either.
MOTS-c doesn't directly trigger the growth hormone gland. The blood readings don't establish your human treatment benefit.
Why do blood timing and the location of fat matter?
When blood was taken. With CJC-1295, average hormone levels and low points between bursts rose [5]. Separate bursts continued. About forty minutes after ipamorelin entered a vein, growth hormone peaked [9].
A later draw could miss the rise in your blood.
Which protein changed. The gland sends growth hormone into blood in short bursts. The liver's growth-supporting protein changes more slowly. Other proteins changed in a separate CJC-1295 study [3]. Your doctor can't use those early findings in place of hormone and liver protein tests.
Different protein tests don't give your doctor the same information.
Natural MOTS-c readings measure what your body already makes. You can't use them to establish an added shot's effects. Human treatment needs its benefit and harms tested separately.
Where fat decreased. With tesamorelin, scans separated fat within patients' livers from fat surrounding internal organs [13][15][17]. Your scale can't separate those stores. MOTS-c improved mouse treadmill tests rather than human recovery [21].
Which animals were ill. Ferrets lost weight while receiving cancer medicine [6]. Rat tests measured bone length [10]; mouse tests measured muscle loss [18]. You can't combine those different tests into one proved human benefit.
What can you conclude without reading every lab detail?
Tesamorelin reduced internal fat in HIV patients with uneven fat buildup [13][15][17]. The liver's protein and growth hormone remained higher for days after CJC-1295 [4][5]. Ipamorelin briefly raised growth hormone [9][11].
Its Phase 2 bowel study didn't establish quicker recovery [8].
MOTS-c cell and animal results still lack human treatment confirmation [18][20][21][22].
You can understand these findings without expecting a personal benefit. A blood test must detect the intended hormone or peptide. Wrong detection can suggest a body change that didn't occur.
Your bottle's label can't establish its contents or effects.
A late blood draw may also miss an earlier peak. That helps explain why separate hormone studies can differ. Other researchers need to repeat promising findings to check them. You don't have to inspect those details to understand the uncertainty.
Two raised readings don't establish less fat or faster recovery.
Your hoped-for benefit needs that body change measured directly. You need the answer kept with the group tested.